Piperacillin Sodium / Tazobactam Sodium
Pronouncation: (PI-per-a-SIL-in SO-dee-um/TAZ-oh-BAK-tam)Class: Antibiotic, Extended spectrum penicillin
Trade Names:
Zosyn
- Powder for Injection 2 g piperacillin, 0.25 g tazobactam
- Powder for Injection 3 g piperacillin, 0.375 g tazobactam
- Powder for Injection 4 g piperacillin, 0.5 g tazobactam
- Powder for Injection 36 g piperacillin, 4.5 g tazobactam (bulk)
- Solution for injection 2 g piperacillin, 0.25 g tazobactam
- Solution for injection 3 g piperacillin, 0.375 g tazobactam
- Solution for injection 4 g piperacillin, 0.5 g tazobactam
Pharmacology
Feedback for Piperacillin Sodium/Tazobactam Sodium
|
Inhibits bacterial cell wall mucopeptide synthesis.
Indications and Usage
Treatment of moderate to severe infections caused by piperacillin-resistant piperacillin/tazobactam-susceptible, β-lactamase producing strains of microorganisms in the following conditions: appendicitis (complicated by rupture or abscess); uncomplicated and complicated skin and skin structure infections; postpartum endometritis or pelvic inflammatory disease; community-acquired pneumonia (moderate severity only); nosocomial pneumonia (moderate to severe).
Contraindications
History of allergic reactions to penicillins, cephalosporins, or β-lactamase inhibitors; hypersensitivity to any component of the product.
Dosage and Administration
Administer by IV infusion over 30 min.
Nosocomial PneumoniaAdults
IV Start with 4.5 g every 6 h plus an aminoglycoside (administered separately) for 7 to 14 days.
Healthy Renal Function (CrCl 90 mL/min or more)Adults
IV 3.375 g every 6 h totaling 13.5 g (piperacillin 12 g/tazobactam 1.5 g) for 7 to 10 days.
Children 2 mo of age and olderIV Piperacillin 80 mg/tazobactam 10 mg per kg every 8 h. Children weighing more than 40 kg with healthy renal function should receive the adult dose.
Children with appendicitis and/or peritonitis 2 mo of age and olderIV Children between 2 and 9 mo of age – piperacillin 80 mg/tazobactam 10 mg per kg every 8 h. Children 9 mo of age and older weighing up to 40 kg – piperacillin 100 mg/tazobactam 12.5 mg per kg every 8 h. Children weighing more than 40 kg – Administer the adult dose.
Renal Function ImpairmentAdults
IV CrCl greater than 40 mL/min – 3.375 g every 6 h (all indications), and 4.5 g every 6 h (nosocomial pneumonia). CrCl 20 to 40 mL/min – 2.25 g every 6 h (all indications), and 3.375 g every 6 h (nosocomial pneumonia). CrCl less than 20 mL/min – 2.25 g every 8 h (all indications), and 2.25 g every 6 h (nosocomial pneumonia). There are no dosage recommendations for children with renal function impairment.
HemodialysisAdults
IV Max dosage 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other indications plus one additional dose of 0.75 g following each dialysis period.
Continuous Ambulatory Peritoneal Dialysis (CAPD)Adults
IV 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other indications.
General Advice
- For IV infusion only. Not for intradermal, subcutaneous, IM, IV bolus, or intraarterial administration. May be used in ambulatory IV infusion pump.
- Multiple concentrations are available for reconstitution. Ensure proper concentration is being used.
- If using ADD-Vantage antibiotic vial, carefully follow manufacturer's instructions for assembling vial and flexible 50 or 100 mL diluent container, reconstituting drug, and preparation for administration.
- If using regular vial with powder for injection, reconstitute with sterile or bacteriostatic water for injection, sterile or bacteriostatic sodium chloride for injection, or dextrose 5% injection. Add 5 mL diluent per gram of piperacillin being reconstituted and swirl until dissolved.
- Further dilute reconstituted solution with compatible diluent to prescribed volume (eg, 50 to 150 mL).
- Do not administer if solution is cloudy, discolored, or contains particulate matter.
- Administer as intermittent infusion over 30 min by direct injection or through a Y-type IV infusion set already in place. If using Y-type IV infusion set, temporarily discontinue administration of any other solution during infusion of piperacillin.
Storage/Stability
- Store powder for injection at controlled room temperature (68° to 77°F). Use reconstituted solution immediately or dilute for infusion. Discard any unused portion after 24 h if stored at room temperature or after 48 h if stored in refrigerator (36° to 46°F). Do not freeze vials after reconstitution.
- Diluted solution in IV bags is stable for up to 24 h at room temperature and up to 7 days if refrigerated.
- Admixed solution in the ADD-Vantage system is stable for up to 24 h at room temperature. Do not refrigerate or freeze the admixed ADD-Vantage system solution after reconstitution.
- Diluted solution in ambulatory IV infusion pump is stable for up to 12 h.
- Store premixed, frozen solutions at or below 4°F. Thaw at room temperature (72°F) or in refrigerator (39°F). Do not force thaw by immersion in water baths or by microwave irradiation. Thawed solution is stable for 24 h at room temperature or 7 days if refrigerated. Do not refreeze thawed solutions.
Drug Interactions
AminoglycosidesMay form microbiologically inactive complexes and should not be mixed in the same container.
Anticoagulants/HeparinFrequently monitor coagulation parameters.
MethotrexateMay reduce Cl of methotrexate.
ProbenecidIncreases and prolongs t ½ of penicillin levels.
VecuroniumNeuromuscular blockade may be prolonged.
Incompatibility
Ringer's lactate solution.
Laboratory Test Interactions
False-positive reaction for glucose in the urine using a copper-reduction method (eg, Clinitest ) but not with enzyme-based tests (eg, Diastix , Tes-Tape ). False-positive results for Aspergillus have been reported using the Bio-Rad Laboratories' Platelia Aspergillus EIA test
Adverse Reactions
The incidences stated for the following adverse reactions were reported with piperacillin/tazobactam administration alone. Adverse reactions occurring with administration of piperacillin/tazobactam in combination with other antibiotics (eg, an aminoglycoside) are not included. Adverse reactions occurring in children are similar to those reported in adults.
Cardiovascular
Hypertension (2%); chest pain (1%).
CNS
Headache (8%); insomnia (7%); agitation (2%); anxiety, dizziness (1%).
Dermatologic
Rash, including maculopapular, bullous, urticarial, and eczematoid (4%); pruritus (3%); erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (postmarketing).
EENT
Rhinitis (1%).
GI
Diarrhea (11%); constipation (8%); nausea (7%); dyspepsia, vomiting (3%); stool changes (2%); abdominal pain (1%).
Genitourinary
Interstitial nephritis, renal failure (postmarketing).
Hematologic-Lymphatic
Agranulocytosis, anemia, hemolytic anemia, pancytopenia, thrombocytosis (postmarketing).
Hepatic
Cholestatic jaundice, hepatitis (postmarketing).
Hypersensitivity
Anaphylactic/anaphylactoid reactions, including shock (postmarketing).
Local
Phlebitis (1%).
Musculoskeletal
Prolonged muscle relaxation (piperacillin alone).
Respiratory
Dyspnea (1%).
Miscellaneous
Fever, moniliasis, pain (2%); edema (1%); candidal superinfections (postmarketing).
Precautions
MonitorPeriodically assess hematopoietic function, especially with prolonged therapy (ie, 21 days or more). |
Pregnancy
Category B .
Lactation
PiperacillinExcreted in low concentrations in human milk.
TazobactamUndetermined.
Children
Safety and efficacy not established in children younger than 2 mo of age.
Elderly
Use with caution, usually starting at the low end of the dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
Hypersensitivity
Serious and sometimes fatal hypersensitivity reactions have occurred.
Renal Function
Adjust dose accordingly.
Superinfection
Prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Bleeding abnormalities
Hemorrhagic manifestations associated with abnormalities of coagulation tests (bleeding time, PT, platelet aggregation) may occur. Abnormalities should revert to normal when drug is discontinued.
Cystic fibrosis patients
May experience higher incidence of adverse reactions when treated with piperacillin.
Neuromuscular excitability/convulsions
May occur if higher than recommended doses are used.
Prophylactic use
Is unlikely to provide benefit and may increase risk of development of drug-resistant bacteria.
Pseudomembranous colitis
May occur because of overgrowth of Clostridium difficile ; consider the possibility in patients in whom diarrhea develops.
Sodium content
Product contains 2.79 mEq (64 mg) of sodium, which should be considered when treating patients requiring restricted sodium intake.
Overdosage
Symptoms
Convulsions, diarrhea, nausea, neuromuscular excitability, vomiting.
Patient Information
- Advise patient or caregiver that medication will be prepared by health care provider and administered in a health care setting.
- Review dosing schedule and prescribed length of therapy with patient. Advise patient that dose, dosing frequency, and duration of therapy are dependent on site of infection, severity of infection, and response to treatment.
- Advise patient or caregiver to immediately inform health care provider if injection-site pain or redness, skin rash, hives, itching, or shortness of breath occur during treatment.
- Advise patient or caregiver to report the following signs of superinfection to health care provider: black “furry” tongue, foul-smelling stools, vaginal itching or discharge, white patches in mouth.
- Warn patient or caregiver that diarrhea containing blood or pus may be a sign of a serious disorder and, if noted after discharge, to seek medical care and not treat at home.
| Link to this page | ![]() |
Printable Version | ![]() |
Email Page | ![]() |
Add to my drug list |
Urinary Tract Infection, Skin Infection, Pneumonia, Kidney Infections, Pelvic Inflammatory Disease, Bone infection, Intraabdominal Infection, Aspiration Pneumonia, Deep Neck Infection, Febrile Neutropenia, Peritonitis, Joint Infection, Bacteremia, Nosocomial Pneumonia, Endometritis, Appendectomy










